← Evidence map

ArticleFrontiers in oncology2026

Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade.

Abdul Shahid Poovathum Parambil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade. | OpenQuestion